Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03DJT
|
||||
| Former ID |
DIB013439
|
||||
| Drug Name |
Bococizumab
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Pfizer
|
||||
| Target and Pathway | |||||
| Target(s) | Proprotein convertase subtilisin/kexin type 9 | Target Info | [532996] | ||
| WikiPathways | PCSK9-mediated LDLR degradation | ||||
| References | |||||
| Ref 525217 | ClinicalTrials.gov (NCT02458287) Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia. | ||||
| Ref 542700 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7730). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.